United States

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

27 Feb 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Wed, Feb 22 2017

BRIEF-Bluebird bio qtrly net loss per share $1.88

* Bluebird Bio reports fourth quarter and full year 2016 financial results and recent operational progress

Medigene eyeing more immunotherapy deals after Bluebird pact

FRANKFURT German biotech firm Medigene said it is drawing more interest from prospective alliance partners for its technology to boost the immune response to cancer after its deal with U.S. peer Bluebird Bio.

Bluebird, Celgene myeloma treatment impresses in tiny study

Patients who previously were not helped by repeated treatments for multiple myeloma showed strong benefits from a new type of therapy in a small study, and with no worrisome side effects, drugmaker Bluebird Bio Inc said on Wednesday.

BRIEF-Bluebird Bio qtrly loss per share $2.07

* Says HGB-207 and all studies of lentiglobin to incorporate manufacturing process 2 going forward

BRIEF-Bluebird Bio provides update on Lentiglobin programs

* Bluebird Bio provides update on Lentiglobin programs and research and development strategy at gene therapy day

BRIEF-Bluebird Bio's LentiGlobin investigational gene therapy accepted into Europen Medicines Agency's PRIME program

* LentiGlobin(TM) investigational gene therapy for transfusion-dependent beta-thalassemia accepted into European Medicines Agency's PRIME program Source text for Eikon: Further company coverage:

Select another date:

More From Around the Web